Eurizon Capital SGR S.p.A. Purchases New Position in Cencora, Inc. $COR

Eurizon Capital SGR S.p.A. purchased a new stake in shares of Cencora, Inc. (NYSE:COR) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 85,529 shares of the company’s stock, valued at approximately $28,892,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares during the last quarter. AustralianSuper Pty Ltd bought a new stake in shares of Cencora during the 3rd quarter valued at approximately $26,191,000. Mediolanum International Funds Ltd grew its holdings in shares of Cencora by 133.0% during the 3rd quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after purchasing an additional 32,138 shares during the last quarter. Chilton Investment Co. Inc. bought a new stake in shares of Cencora during the 3rd quarter valued at approximately $459,000. Finally, Advisors Asset Management Inc. grew its holdings in shares of Cencora by 40.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after purchasing an additional 4,973 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Stock Up 0.6%

Shares of NYSE COR opened at $269.21 on Friday. The company has a market capitalization of $52.38 billion, a P/E ratio of 20.65, a price-to-earnings-growth ratio of 1.24 and a beta of 0.64. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The company’s 50 day moving average price is $298.56 and its 200-day moving average price is $333.91.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its board has initiated a share buyback plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be given a $0.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s payout ratio is 18.40%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Morgan Stanley set a $342.00 price target on shares of Cencora in a report on Friday, May 8th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Citigroup reduced their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Finally, Barclays boosted their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.